OLDWICK, N.J., Jan. 3, 2019 /PRNewswire/ -- Provention Bio,
Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company
dedicated to developing novel therapeutics aimed at intercepting
and preventing immune-mediated diseases, announced today that an
article supporting the development of a vaccine for Type 1 Diabetes
(T1D) by targeting coxsackievirus B (CVB) infection was published
in the December 2018 online issue of
Expert Review of Vaccines.
The publication, titled, Developing a Vaccine for Type 1
Diabetes by Targeting Coxsackievirus B, is authored by Dr.
Heikki Hyöty, Faculty of Medicine and Life Science, Department of
Virology at the University of Tampere in Tampere,
Finland; Dr. Mikael Knip of
Children's Hospital, University of
Helsinki and Helsinki University
Hospital in Helsinki, Finland; and
Dr. Francisco Leon, Provention's
co-founder and Chief Scientific Officer.
The peer-reviewed article highlights research that pinpoints
enterovirus infections, specifically CVB, as a possible cause of
T1D. The article further describes ongoing progress on what
could be the first human vaccine for T1D, PRV-101. PRV-101 is
a polyvalent vaccine currently being developed by Provention as a
vaccine for acute coxsackie infection and to potentially prevent up
to 50% of worldwide T1D cases. PRV-101 is currently in an
IND-enabling stage prior to initiation of first-in-human
studies.
"Epidemiological and experimental studies indicate that
approximately half of all T1D cases could be triggered by a CVB
infection in early childhood," said Dr. Leon. "Based on this
groundbreaking research, Provention Bio is advancing PRV-101 as the
first-ever CVB vaccine designed to prevent acute infection and
potentially T1D. In addition to the potential prevention of
T1D, this vaccine could have other important beneficial health
effects generated by protection against acute CVB infections, which
are frequent and cause significant morbidity particularly in young
children. On behalf of Provention, I would like to commend Drs.
Hyöty and Knip for leading this very important
research."
About Provention Bio, Inc.
Provention Bio, Inc.
(Nasdaq: PRVB) is a clinical-stage biopharmaceutical company
leveraging a transformational drug development strategy that is
focused on the prevention or interception of immune-mediated
disease. Provention's mission is to in-license, transform and
develop therapeutic candidates targeting the high morbidity,
mortality and escalating costs of autoimmune and inflammatory
diseases including: type 1 diabetes (T1D), Crohn's disease,
ulcerative colitis, celiac disease, lupus, and certain
life-threatening viral diseases. Provention's diversified portfolio
includes advanced-stage product development candidates that have
undergone clinical testing by other companies. For more information
on Provention Bio, please visit www.proventionbio.com.
Forward Looking Statements
Certain statements in
this press release are forward-looking within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements
may be identified by the use of forward-looking words such as
"anticipate," "believe," "forecast," "estimate," "expect," and
"intend," among others. These forward-looking statements are based
on Provention's current expectations and actual results could
differ materially. There are a number of factors that
could cause actual events to differ materially from those indicated
by such forward-looking statements. These factors include, but are
not limited to, risks related to failure to obtain FDA approvals or
clearances and noncompliance with FDA regulations; uncertainties of
patent protection and litigation; limited research and development
efforts and dependence upon third parties; substantial competition;
our need for additional financing and the risks listed under "Risk
factors" in our quarterly report on Form 10-Q for the quarter ended
September 30, 2018 and any subsequent
filings with the Securities and Exchange Commission (SEC). As with
any pharmaceutical under development, there are significant risks
in the development, regulatory approval and commercialization of
new products. Provention does not undertake an obligation to update
or revise any forward-looking statement. The information set forth
herein speaks only as of the date hereof.
***
Media & Investor Contacts
Jason Rando / Joshua
Drumm, Ph.D.
Tiberend Strategic Advisors, Inc.
T: 212 375 2665 / 212 375 2664
jrando@tiberend.com
jdrumm@tiberend.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/provention-bio-announces-publication-in-expert-review-of-vaccines-describing-the-scientific-rationale-for-developing-a-vaccine-for-type-1-diabetes-by-targeting-coxsackievirus-b-300771926.html
SOURCE Provention Bio, Inc.